A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Hormone Receptor Positive Breast Carcinoma|HER2-negative Breast Cancer
Interventions: DRUG: OP-1250
Sponsor: Olema Pharmaceuticals, Inc.